Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Medicure Inc. (MCUJF : OTC)

• Company Description    Medicure Inc is a cardiovascular drug discovery and development company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine. In addition to MC-4232, they are also conducting Phase II clinical trials with MC-1, which is focused on the prevention and treatment of ischemia, ischemic reperfusion injury, and stroke. Number of Employees: 23

• Price / Volume Information    Yesterday's Closing Price: $0.86 Daily Weekly Monthly 20 Day Moving Average: 575 shares Shares Outstanding: 10.44 (millions) Market Capitalization: $8.99 (millions) Beta: 1.06 52 Week High: $0.94 52 Week Low: $0.44 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -0.17% -3.91% 12 Week 59.54% 34.19% Year To Date 38.95% 30.13%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2 - 1250 Waverley Street - WINNIPEG,A2 R3T 6C6 CAN ph: 204-487-7412 fax: 204-488-9823 ir@medicure.com http://www.medicure.com

• General Corporate Information    Officers Albert D. Friesen - Chairman and Chief Executive Officer Neil Owens - President and Chief Operating Officer Haaris Uddin - Chief Financial Officer Reuben Saba - Vice-President Arnold Naimark - Director Peer Information Medicure Inc. (GSAC) Medicure Inc. (CASI) Medicure Inc. (ALCD.) Medicure Inc. (OMNN) Medicure Inc. (CGPI.) Medicure Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 58469E408 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 10.44 Most Recent Split Date: 11.00 (0.07:1) Beta: 1.06 Market Capitalization: $8.99 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.64 Price/Cash Flow: 9.66 Price / Sales: 0.58 EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -25.00% Sales Growth vs. Year Ago Period: -9.56% vs. Previous Quarter: -9.33% ROE 06/30/25 - - 03/31/25 - -8.74 12/31/24 - -5.05 ROA 06/30/25 - - 03/31/25 - -6.05 12/31/24 - -3.54 Current Ratio 06/30/25 - - 03/31/25 - 1.71 12/31/24 - 1.89 Quick Ratio 06/30/25 - - 03/31/25 - 1.29 12/31/24 - 1.50 Operating Margin 06/30/25 - - 03/31/25 - -8.14 12/31/24 - -4.68 Net Margin 06/30/25 - - 03/31/25 - -8.15 12/31/24 - -4.68 Pre-Tax Margin 06/30/25 - - 03/31/25 - -6.99 12/31/24 - -3.57 Book Value 06/30/25 - - 03/31/25 - 1.34 12/31/24 - 1.45 Inventory Turnover 06/30/25 - - 03/31/25 - 2.72 12/31/24 - 2.59 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.02 12/31/24 - 0.02 Debt-to-Capital 06/30/25 - - 03/31/25 - 2.17 12/31/24 - 2.38

Powered by Zacks Investment Research ©